Kono Chem Co.,Ltd
Country: China (Mainland)
Year Established: 2012
Business License:
Business type: Other
Product Certificate:(1)
- HALAL
Contact Details | Similar Products

Mr.Sam
Ms.Sarah
Mr.Edward

Communicate with Supplier:

: Mr. Hong: What can I do for you?

Raloxifene CAS NO.84449-90-1

Min.Order Quantity:: 500 Gram

Purity:: 99.90%

Port:: Beijing or Guangzhou

Payment Terms:: T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

Raloxifene
84449-90-1
Raloxifene,CAS no 84449-90-1

Quick Details

ProName: Raloxifene
CasNo: 84449-90-1
Molecular Formula: C28H27NO4S
Appearance: solid or liquid
Application: for pharma use
DeliveryTime: Prompt
PackAge: drum and bag
Port: Beijing or Guangzhou
ProductionCapacity: 1 Metric Ton/Year
Purity: 99.90%
Storage: in sealed air resistant place
Transportation: by sea or air
LimitNum: 500 Gram
Related Substances: NMT0.001%
Residue on Ignition: 0.00%
Heavy Metal: NMT1ppm
Valid Period: 2 years

Superiority

specifications

cas no.:: 84449-90-1

other names:: raloxifene hydrochloride

mf:: c28h27no4s

einecs no.:: n/a

place of origin:: shandong, china (mainland)

type:: antineoplastic agents

grade standard:: medicine grade

usage:: animal pharmaceuticals

brand name:: kono

model number:: /

purity:: 99%

molecular weight:: 475.5992

density:: 1.285g/cm3

boiling point:: 687.5°c at 760 mmhg

refractive index:: 1.654

flash point:: 369.6°c

vapour pressur:: 1.56e-19mmhg at 25°c

physical state:: solid

storage:: store at -20° c

refractive index:: n20d 1.65 (predicted)

melting point:: 257.8 °c

packaging & delivery

packaging details:: 10g/bag,100g/bag,1kg/bag,25kg/drum
prompt shipment after receipt of your order confirmation

delivery detail:: shipped in 3 days after payment

Details

introduction:

raloxifene (marketed as evista by eli lilly and company) is an oral selective estrogen receptor modulator (serm) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. it is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

specification:

items	standard		results
appearance	yellowish powder		comply
identification	ir		comply
	it meets the requirements of the test for choride		comply
solubility	soluble in 10% sodium hydroxide solution, slightly soluble in methanol, insoluble in water		comply
assay	98.5%~101.5%		99.27%
related substances	≤0.20% rrt=0.74 impurity	≤0.2%	comply
	other single impurity	≤0.1%	0.09%
	total impurities	≤0.5%	0.36%
loss on drying	≤0.5%		0.08%
residue on ignition	≤0.1%		comply
heavy metals	≤10ppm		comply
storage	preserve in well-closed containers and protected from light. store at room temperature
determination	complies with usp32 standard

medical use
raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. it is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.for either osteoporosis treatment or prevention, supplemental calcium and/or vitamin d should be added to the diet if daily intake is inadequate.

Post a RFQ

Cas No.:

Product Name:

Quantity: